Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentral Adelaide Local Health Network Incorporated
About this trial
The goal of this clinical trial is to compare responses to Varicella Zoster vaccination between transplant patients on different medication regimens, and their healthy co-habitants. The main questions it aims to answer are:
1. Are there differences in vaccination immunological responses in transplant patients on different immunosuppression regimens? 2. Are there differences in vaccination immunological responses between transplant patients and their healthy co-habitants? Participants will all receive a 2-dose course of SHINGRIX recombinant Zoster vaccination, and have immunological responses measured and compared at 5 timepoints between 1 week to 1 year post-vaccination.
Eligibility criteria
Qualifiers
Population - Group 1. Healthy co-habitants (n = 30)
Household co-habitant of transplant recipient in trial
Aged >50 years
Previous documented infection with VZV (known infection history or positive VZV IgG result)
Disqualifiers
Aged <50 years
Unable or unwilling to provide informed consent to participate in the trial
Known allergy to or intolerance of the contents of the RZV vaccine
No previous infection with VZV (chickenpox)
Trial design
Treatments tested in this trial
- Recombinant zoster vaccine adjuvanted (SHINGRIX)
Treatment groups
160 Participants
are divided into 1 treatment groupSponsors and collaborators
Central Adelaide Local Health Network Incorporated
Lead sponsor
National Health and Medical Research Council, Australia
Collaborator
University of Adelaide
Collaborator
Royal Prince Alfred Hospital, Sydney, Australia
Collaborator
Source ClinicalTrials.gov